HOTH

Hoth Therapeutics (HOTH)

About Hoth Therapeutics (HOTH)

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Details

Daily high

$0.82

Daily low

$0.73

Price at open

$0.76

52 Week High

$1.73

52 Week Low

$0.58

Market cap

5.6M

Dividend yield

0.00%

Volume

155,663

Avg. volume

142,974

P/E ratio

-.58

Hoth Therapeutics News